key: cord-0798953-mgl5wg56 authors: Procaccini, Fabio L; Alcázar Arroyo, Roberto; Albalate Ramón, Marta; Torres Aguilera, Esther; Navarro, Juan Martín; Ryan Murua, Pablo; Cintra Cabrera, Melissa; Ortega Díaz, Mayra; Puerta Carretero, Marta; de Sequera Ortiz, Patricia title: Acute kidney injury in 3182 patients admitted with COVID-19: a single center retrospective case-control study date: 2021-01-28 journal: Clin Kidney J DOI: 10.1093/ckj/sfab021 sha: e813eefef763b48208b618ae30490b977061afad doc_id: 798953 cord_uid: mgl5wg56 BACKGROUND: Acute kidney injury (AKI) may develop in COVID-19 patients and may be associated with a worse outcome. The aim of this study is to describe AKI incidence during the first 45 days of the SARS-CoV2 pandemic in Spain, its reversibility and the association with mortality. METHODS: Observational retrospective case-control study based on patients hospitalized between March 1 and April 15, 2020 with SARS-CoV2 infection and AKI. Confirmed AKI cases were compared with stable kidney function patients for baseline characteristics, analytical data, treatment and renal outcome. Patients with end-stage kidney disease were excluded. RESULTS: AKI incidence was 17.22% among 3182 admitted COVID-19 patients and acute kidney disease (AKD) incidence was 6.82%. The most frequent causes of AKI were prerenal (68.8%) and sepsis (21.9%). Odds ratio for AKI was increased in patients with pre-existent hypertension (OR 2.58, 95% CI 1.71-3.89) and chronic kidney disease (OR 2.14, 95% CI 1.33-3.42) and in those with respiratory distress (OR 2.37, 95% CI 1.52-3.70). Low arterial pressure at admission increased the risk for stage 3 AKI (OR 1.65, 95% CI 1.09-2.50). Baseline kidney function was not recovered in 45.73% of overall AKI cases and in 52.75% of AKI patients with prior chronic kidney disease. Mortality was 38.5% compared to 13.4% of the overall sample population. AKI increased mortality risk at any time of hospitalization (HR 1.45, 95% CI 1.09-1.93). CONCLUSIONS: AKI is frequent in COVID-19 patients and is associated to mortality, independently from acute respiratory distress syndrome. AKD was also frequent and merits adequate follow-up. Since the first case reports were published describing SARS-CoV2 infections in China, there were suggestions that pulmonary tissue was not the only SARS-CoV2 target and nephrologists focused on acute kidney injury (AKI) as an important complication of hospitalized patients with acute respiratory distress syndrome (ARDS). 1, 2 Reports from around the world underlined a high rate of AKI among COVID-19 patients and the need for renal replacement therapy (RRT). converting enzyme 2 (ACE2) and the transmembrane serine protease 2 (TMPRSS2) as entrance to human cells and these proteins locate to multiple organs as brain, oral mucosa, small intestine and kidney. 3, 4 Abundant ACE2 staining was observed in the brush border of the kidney proximal tubular cells and weak cytoplasmic staining in distal tubules and collecting ducts 3 . ACE2 and TMPRSS2 genes are co-expressed in proximal tubule cells and podocytes. 5 Series of kidney histology from China describe acute tubular necrosis as the main finding and identify viral particles in kidney tissue. 6 Clinical presentation of kidney injury ranged from mild microhematuria and proteinuria to severe AKI, but information about the real magnitude of the problem is scarce, and the exact physiopathology of kidney injury is yet to be determined. 7 The aim of this study was to determine the incidence of AKI in patients with acute SARS-CoV2 infection in the first 45 days of pandemic in a hospital located in one of the most affected areas of Spain and Madrid, where almost 60.000 people were diagnosed between March and May 2020 and seroprevalence of SARS-CoV2 in the population was 11.7%. 8, 9 Moreover, we try to identify risk factors for AKI and mortality risk outcomes of COVID-19 patients with AKI. This is an observational case-control study analysing AKI incidence in hospitalized patients with SARS-CoV2 infection at Hospital Universitario Infanta Leonor (HUIL) between March 1 st and April 15 th , 2020. This is a secondary hospital attending a population of 345.206 inhabitants, with 269 beds for hospitalization and 8 intensive care unit (ICU) beds. During the pandemic, the hospital was reconverted to a COVID-19 hospital with 720 beds and 34 ICU beds. The study was approved by the scientific ethical committee of HUIL. CoV2 virus or on high clinical suspicion based on epidemiological data (direct contact with a positive case), clinical status, blood parameters (lymphopenia, increase in D-dimer, liver enzymes, fibrinogen and C-reactive protein) and X-ray or computed tomography imaging. 10, 11, 12 Patients were considered for in-hospital care when they developed hypoxemic respiratory failure, sepsis, septic shock, or extensive viral pneumonia in radiological findings (alveolar consolidation with peripheral distribution, round-glass opacities, interlobular septal thickening, pleural thickening, crazy-paving pattern). 13 Main data about hospitalization as sex, age, date of admission, death or discharge were collected from official hospital registries. Multiple hospitalizations due to the same clinical condition were considered as a unique admission time. Follow-up ended with death or with last analytical data available from primary care within 60 days after first admission. Patients with chronic kidney disease (CKD) stage 5 (eGFR <15 mL/min/1.73m2) or in RRT were excluded. As most patients with renal impairment were not directly referred to nephrological assessment, all patients with serum creatinine (sCr) greater than or equal to 1.3 mg/dL during the hospitalization were retrospectively identified from the central laboratory system. After that, renal function of every patient was revised whether they met AKI criteria. AKI was defined as an increase in sCr greater than or equal to 0.3 mg/dL over baseline sCr. Urine output was not considered due to lack of reliable data. The highest sCr value within a retrospective span of 1 year was considered as the baseline kidney function, and these data were collected from primary care electronical records (HORUS healthcare software) and from nephrology department registries when available. AKI etiology was categorized as sepsis, prerenal, intrinsic renal, postrenal and unknown. Etiology was the reported in the official clinical registries. In most cases it was not reported, so etiology was defined retrospectively by a team of eight expert nephrologists based on analytical data, vital signs, and clinical evolution. Every nephrologist assessed different patients and only in case of unclear etiology the case was discussed with a senior member and both had to agree on the final assignment. AKI secondary to severe sepsis included patients with at least two of these conditions: evidence of hypotension refractory to fluid repletion, tissue hypoperfusion, organ dysfunction, multiple organ failure or a Quick Sequential Organ Failure Assessment (qSOFA) score >1. Haemodynamic prerenal state was considered in case of reported clinical sign of hypovolemia caused by dehydration, haemorrhage, diuretics, gastrointestinal fluid loss, use of drug that affect glomerular hemodynamic and hypotension with response to fluid administration and fall of sCr within 72h from peak. Intrinsic renal damage was considered when sCr decline started >72h or was induced by nephrotoxic drugs (antibiotics, antineoplastic drugs, contrast media, anaesthetic drugs). All patients with glomerular disease were diagnosed before the start of this study and directly assessed by a nephrologist during the hospitalization. No kidney biopsies were performed during the study period. Post-renal disease was considered when a urinary tract obstruction was described by ultrasonography or resolution after bladder catheterization. AKI was classified as unknown when it was impossible to determine a clear etiology. AKI was classified inside the main categories as drug-related only if the drug was considered to have a main role in the development of AKI and in two prescription situations: if a new drug was identified before the development of AKI, and it was chronologically compatible; if a drug was not discontinued within a new clinical situation. AKI was staged according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. 14 Acute kidney disease (AKD) was defined according to consensus from Acute Disease Quality Initiative (ADQI) as a loss of kidney function for a duration >7 days after exposure to an AKI initiating event 15 AKI resolution was defined as return to baseline value of sCr. For chronic kidney disease (CKD) patients a final value >25% from baseline was considered as no resolution. After establishing the cases cohort, a control group of the same size was generated from the main pool of patients admitted to the hospital in the same period and with sCr <1.3 mg/dL. A numeric identifier was assigned to any eligible patient, then STATA 16 (StataCorp LLC) was used to shuffle data randomly and obtain a sample without replacement. Controls were not matched using any variable. During the period of the study COVID19 patients were divided in four categories of priority for ICU admission due to beds shortage, according to guidelines by national society of critically ill professionals 16 . Priority 1 category included critical and unstable patients requiring invasive mechanical ventilation whose monitoring and intensive treatment cannot be provided outside the ICU. Patients with PaO 2 /FiO 2 ratio <200 or <300 and organ failure but with non-invasive ventilation (NIV) were derived towards an intermediate care unit (Priority 2). Patients with terminal chronic disease, cognitive impairment, or degenerative disease, were not admitted (Priority 3 and 4). Mechanical ventilation was not recommended in patients over 80 years. Patients between 70 and 80 years with moderate-severe comorbidities such as chronic heart failure, dilated cardiomyopathy, chronic obstructive pulmonary disease, cirrhosis, and CKD, were assessed case-by-case with preference for NIV. Patients with longest life expectancy were prioritized. RRT was started in AKI characterized by oliguria (urine output <0.3 mL/kg/h for 24 hours), refractory fluid overload, severe hyperkalemia (K >6.5 mEq/L), rapidly rising urea levels (if otherwise unexplained) or severe metabolic acidosis (pH <7.1). RRT was not considered in patients with refractory multiple organ failure. Clinical data were collected from electronical health record system (SELENE -CERNER corporation). All collected data were anonymized and subsequently analysed. Demographic data, baseline risk factors, including CKD, and treatment were recorded, including angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEi), systemic corticosteroids, statins, chemotherapy and biological treatments. Main clinical complications such as heart failure, ARDS, pulmonary embolism, and disseminated intravascular coagulopathy were collected along with experimental COVID-19 treatments. Data from AKI patients included baseline treatment with diuretics and antidiabetic agents and AKI characteristics. Analytical data were recorded only for cases and included lymphocyte counts, hemoglobin, platelet counts, D-dimer, urea, creatinine and C-reactive protein at admission, AKI onset and at day 3 and 7, plus last available control; albumin, sodium, potassium, calcium and bicarbonate levels were recorded at AKI onset. The highest level of lactate dehydrogenase and interleukin-6 was also recorded. Urinary levels of creatinine, sodium and potassium and data concerning proteinuria and hematuria were collected for cases at AKI onset. Glomerular filtration rate (eGFR) was estimated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 17 AKI management and renal outcome were also recorded. Statistical analysis was performed with STATA 16 (StataCorp LLC). Normal distribution of variable was initially tested with box plot and cumulative density function of the normal distribution. Simple association of variables was measured with t-student test, chi2, Fisher´s exact test and pairwise correlations. Variables with p>0.3 in univariate analysis were not considered in multivariate logistic and Cox models. In predictive models backward stepwise selection was performed with 0.10 significance level for removal and 0.05 for addition. In logistic and Cox regression models chunk test and likelihood-ratio test were performed to evaluate real variable effects. Best models were then selected after confounders were analysed (practical difference >10% from reference model). Missing data were not imputed and listwise method was used in the analysis. For Cox regressions proportion hazard assumption was verified for variables in the final best model. 3182 patients were admitted for SARS-CoV2 infection during the study period ( Figure 1 ). Of these, 691 presented sCr greater than or equal to 1.3 mg/dL from which a total of 548 subjects defined the AKI group after excluding dialysis patients, unconfirmed SARS-CoV2 infection and subjects not fulfilling AKI criteria ( Figure 2 ). The overall incidence of AKI among patients hospitalized with COVID-19 was 17.22%. Of these, 389 (12.22% of all COVID-19 patients, 70.99% of AKI patients) presented AKI upon admission, while 159 (5.00% of all COVID-19 patients, 29.01% of AKI patients) developed in-hospital AKI with a median onset time of 3 days (IQR 2-6). The control group was formed by 548 subjects without AKI from the main pool of 2578 subjects with confirmed COVID-19. 83.21% of patients from both groups presented at least 1 chronic clinical condition at admission. Overall median hospitalization time was 9 days (IQR 5-14) and it was longer in AKI than in non-AKI patients (11 vs 8 days, p<0.001). Median follow-up time of AKI patients was 11 days (IQR 5-21). Baseline characteristics of AKI and control groups are shown in Table 1 . AKI patients were older and mostly males, and had a higher prevalence of hypertension, cardiopathy and diabetes. ARDS developed more frequently in the AKI group (32.7 vs 15.3%, p<0.001) as did heart failure, but there were no differences in baseline pulmonary diseases. CKD was more frequent in AKI patients and the most common causes were nephroangiosclerosis (37.61%) and diabetic nephropathy (19.91%) ( Table 2) . AKI stage 1 was predominant with 70.07% (n=384) of cases compared to stage 2 (19.34%, n=106) and stage 3 (10.58%, n=58). Key analytical data and baseline characteristics of AKI patients are listed in Table 3 . The most frequent cause of AKI was prerenal/hemodynamic (68.8%), followed by sepsis (21.9%) ( Table 4 ). Drugs had a role in AKI development in 42.86% of intrinsic renal and 19,62% of hemodynamic cases. Dipstick urinalysis was performed in 125 (22.81%) patients with AKI. Among these, 59 patients presented microhematuria, but in only 26 (44.08%) of them was new-onset microhematuria. There was no difference in new-onset microhematuria between patients with previous normal kidney function and CKD patients (38.46% vs 61.54%, p=0.62). Moreover, 65 patients presented proteinuria above 100mg/dL but in only 25 (38.46%) of them, it was new-onset proteinuria, and in just 6 patients (24%), proteinuria was above 300 mg/dL. Acute kidney disease 217 (6.82% of all COVID19 patients, 39.60% of AKI) patients met AKD criteria with characteristics described in Table 5 . In this subgroup, sepsis and ARDS were less frequent than in AKI non-AKD patients (Table 4 and 5). Median hospitalization time was 15 days (IQR 11-21) vs 7 in no AKD group. In the univariate analysis, hypertension, cardiopathy, diabetes, obesity, CKD, chronic treatment with ARBs, ACEi, statins, low arterial pressure at admission and onset of ARDS and heart failure were all significantly associated with AKI development (Supplemental material S1). In a predictive multiple regression model, hypertension and CKD patients showed an increased risk for AKI, with OR of 2.58 (95% CI 1.71-3.89) and 2.14 (95% CI 1.33-3.42) respectively. ARDS (OR 2.37, 95% CI 1.52-3.70) and hypotension at admission (OR 1.96, 95% CI 1.18-3.26) also showed a higher risk for AKI when adjusted for age in the same model ( Table 6 ). The same risk factors were investigated in the AKD subgroup versus non-AKD confirming CKD as a risk factor with an OR 1.82 (95% CI 1.25-2.65), while ARDS had a OR 0.55 (95% CI 0.37-0.81) ( Table 7 ). In addition, low arterial pressure at admission was associated with AKI severity with an OR 1.65 (95% CI 1.09-2.50) for stage 3 AKI. No association was found with fever, gastrointestinal losses, and baseline treatment with type 2 sodium-glucose cotransporter inhibitors (SGLT2i). No resolution of AKI occurred in 241 (45.73%) patients and in 52.75% of CKD patients. AKI resolution was directly associated with etiology and baseline kidney function (Figure 3-4) , and recovery at 7 days was 33.94% (Table 9 ). Median resolution time in patients with AKD was 13 days (IQR 10-23) vs 4 days (IQR 2-6) in no AKD group. Acidosis, hypernatremia and a high serum level of D-dimer, C-reactive protein (CRP) and lactate dehydrogenase showed association with no resolution of AKI in the univariate Cox regression. In a multivariate model adjusted for CKD and ARDS effect, hypernatremia and acidosis showed a hazard ratio of 2.28 (95% CI 1.43-3.60) and 1.54 (95% CI 1.13-2.10) respectively for no resolution of AKI. (Supplemental material S2). Intravenous treatment with corticosteroids was associated with lower risk of AKI non-recovery (HR 0.71 -95% CI 0.51-0.99). Patients with AKD presented lower levels of CRP (Table 8 ) than others AKI patients and no resolution was significatively more frequent in this group compared to no-AKD (52.63% vs 41.19%, p=0.01). New onset microhematuria or proteinuria were not associated with a worse renal outcome. continuous RRT. 9/44 patients (20.45%) presented criteria for RRT but only after limitation of life support. Of patients with AKI not admitted to the ICU, 36 (6,56%) presented criteria for RRT but did not have access to the treatment because nephrology department was not consulted. Mortality of all patients admitted to the hospital with COVID-19 in the period of the study was 13,42% (427 registered deaths). Mortality in the AKI group was higher than in control group (38.50% vs 13.05%, p<0,001). Mortality among CKD patients with AKI was 41.15%. Median time between AKI and death was 6 days (IQR 2-12), 13 days (IQR 10-18) in the AKD subgroup. Mortality was lower in the AKD subgroup than in the AKI no-AKD subgroup (33.64% vs 41.69%, p=0.05) with a 7-day mortality of 31.57% (Table 9 ). Patients with no resolution of AKI registered more deaths compared to those that recovered from AKI (69.29% vs 12.59%, p<0.001). This study is the first to analyse the AKI incidence in a single secondary COVID-19 hospital of a highly affected area in Spain during the peak of the pandemic, when healthcare was overwhelmed. The main findings are the negative impact of both non-dialysis CKD and AKI on survival, independently of ARDS and persistent AKD for a sizable group of AKI patients. On the 25 th February 2020, the first case of COVID-19 was reported in Madrid and the rapidly evolving spread of the disease disrupted clinical workflows in both primary care and in every hospital department. Since the first patients were admitted, a high AKI incidence and the need for direct nephrological care were observed. Epidemiological data set AKI incidence in hospitalized patients in the pre-COVID-19 era at 10 to 15% with a 10% mortality, although AKI definition often varies from the KDIGO guidelines in published literature. 18, 19 The overall incidence of AKI in this study was 17.22% of hospitalized SARS-CoV2 infected patients. This is higher than early reports from China 20 but lower than published data from the New York city area (22.2%), 21, 22 . In-hospital AKI development of 5% is comparable with results by Cheng et al. 2 SARS-CoV2 primarily affected elderly people that are more prone to AKI due to their comorbidities and their lower renal functional reserve. 23 In the present study 83% of subjects had at least one chronic condition at admission and 41% of AKI cases had CKD. CKD and hypertension were independent risk factors for AKI along with ARDS and low arterial pressure at admission. ACEi and ARBs were associated with AKI but only in univariate analysis, likely representing the coexistence of conditions that sensitize to AKI development. Our data suggest that antihypertensive treatment together with febrile syndrome and limited access to the healthcare system may contribute to AKI development facilitating hypotension at admission. The higher risk of no resolution of AKI in patients with hypernatremia and acidosis, probably defines elderly patients with prerenal state secondary to insufficient water consumption or severe sepsis. Hypernatremia emergency patients with AKI were already reported to have poor outcomes. 24, 25 In this context, CKD patients are a vulnerable population and COVID-19 may aggravate their evolution. CKD increased the risk of both AKI and AKD, and, remarkably, more than half of CKD patients failed to recover baseline renal function, similar to data published by Chan et al. 26 It is less clear whether SARS-CoV-2 may directly injure the nephrons. In this regard, some patients without prior CKD developed new onset microhaematuria and proteinuria. This subgroup did not show a worse outcome, but the low number of collected urine specimens limits the interpretation of these findings. The rate of CRRT was lower than in prior reports and we identified several potential contributors. 27 First, CRRT was only possible in the ICU setting and ICU capacity in our hospital was insufficient to deliver proper medical attention to the whole population at the peak of pandemic. Transfer of ICU patients to other hospitals was not possible until a later stage. Moreover, AKI patients' eligibility was limited by comorbidities and older age. Given the supplies shortage, care for younger patients was prioritized. Anyway, nephrology department was not consulted for many patients achieving RRT criteria probably because of rapidly worsening of respiratory conditions and staff oversaturation. Mortality in AKI patients in the present study was in line with COVID-19 literature reports (8.5% -35%). 21, 28 High mortality in AKI patients may be partly explained by a higher rate of comorbidities, ARDS and older age. However, AKI was an independent risk factor for inhospital mortality in COVID-19 patients apart from ARDS. The additive effect on mortality is more evident in short-lasting AKI when patients present a more severe inflammatory profile and early death precluded them to reach AKD condition. This result should concern nephrologists and all specialists attending COVID-19 patients to optimize treatment based on renal function ( Figure 6 ). When experimental treatments for COVID-19 were analysed, only intravenous corticosteroid administration was associated to higher AKI resolution and lower mortality rates. Hydroxychloroquine showed a similar result, but it may suffer from selection bias because 94% of patients were treated with this drug and untreated patients were often older or at high life risk at admission. This study has potential limitations. AKI may have been underestimated as patients with baseline sCr <1.00 mg/dL were missed by the strategy to identify AKI. Moreover, these patients may have been labeled as controls and some eligible control could present unconfirmed SARS-CoV2 infection. In conclusion AKI is a complication in hospitalized patients with SARS-CoV2 infection associated to increased mortality. Patients with CKD and hypertension are at higher risk to develop AKI and renal function can be compromised after discharge. We hypothesize that continuous antihypertensive drug use without adequate medical supervision in symptomatic COVID-19 patients may have contributed to hypotension and the onset of AKI. A special thanks to all healthcare personnel who participated in patients care during the COVID-19 pandemic. All authors declare no conflicts of interest for any aspect of this manuscript. -S2a -Association of laboratory parameters with acute kidney injury resolution -S2b -Global test of proportional hazards assumption S3 -Association of acute kidney injury with mortality -S3a -Association of acute kidney injury with mortality -S3b -Global test of proportional hazards assumption AKI= Acute kidney Injury, COPD = chronic obstructive pulmonary disease, OSA= obstructive sleep apnoea, ACE = Angiotensinconverting enzyme, ARBs = angiotensin II receptor blockers, PCR = polymerase chain reaction, ARDS = Acute respiratory Distress Syndrome, DIC = disseminated intravascular coagulopathy, PTE = pulmonary thromboembolism, SD = standard deviation. Obesity was defined as a body mass index >30. Immunologic/inflammatory diseases included rheumatologic diseases, chronic inflammatory bowel diseases, multiple sclerosis, miastenia gravis and thyroid autoimmune diseases. Patients with sCr<1.3 mg/dL were not actively revised to confirm COVID-19 criteria. Eligible controls were randomly sampled to obtain a control group of the same size of cases group. All patients in case and control group were actively revised to confirm COVID-19 criteria. AKI=Acute kidney injury, CKD = chronic kidney disease, sCr= serum creatinine China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China Kidney disease is associated with in-hospital death of patients with COVID-19 Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate World Health Organization. Global Surveillance for human infection with coronavirus disease (COVID-19) Interim guidance World Health Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance Interpretation of CT signs of 2019 novel coronavirus (COVID-19) pneumonia COVID-19) Outbreak: What the Department of Radiology Should Know KDIGO clinical practice guidelines for acute kidney injury Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup Recomendaciones éticas para la toma de decisiones difíciles en las unidades de cuidados intensivos ante la situación excepcional de crisis por la pandemia por COVID-19: revisión rápida y consenso de expertos [Ethical recommendations for a difficult decision-making in intensive care units due to the exceptional situation of crisis by the COVID-19 pandemia: A Preliminary official reports from ENE-COVID19 study: national study of seroepidemiology for SARS-CoV2 infection in Spain Clinical Decision Support for In-Hospital AKI Acute kidney injury Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Acute kidney injury in patients hospitalized with COVID-19